Late-onset myasthenia gravis: A review when incidence in older adults keeps increasing

Muscle and Nerve

Volumn 48, Issue 5, 2013, Pages 705-710

  Alkhawajah, Nuha M ^a   Oger, Joel ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Late onset; Myasthenia gravis; Older adults; Thymectomy; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN G; LIVE VACCINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PROTEIN TYROSINE KINASE; PYRIDOSTIGMINE; RITUXIMAB; TACROLIMUS;

ARTICLE; BRAIN ELECTROPHYSIOLOGY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; EARLY DIAGNOSIS; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLUENZA; INFLUENZA VACCINATION; MYASTHENIA GRAVIS; NEPHROTOXICITY; NEUROIMMUNOLOGY; NEUROMUSCULAR SYNAPSE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THYMECTOMY; THYMOMA; UNSPECIFIED SIDE EFFECT;

LATE ONSET; MYASTHENIA GRAVIS; OLDER ADULTS; THYMECTOMY; TREATMENT;

AGE OF ONSET; AGED; HUMANS; INCIDENCE; MYASTHENIA GRAVIS;

EID: 84886740529     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23964     Document Type: Article

References (64)

1. Neugarten B. Age groups in American society and rise of young-old. Ann Am Acad Polit Soc Sci 1974;415:187-198.
2. Compston DA, Vincent A, Newsom-Davis J, Batchelor JR. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 1980;103:579-601.
3. Aarli JA. Myasthenia gravis in the elderly: is it different? Ann NY Acad Sci 2008;1132:238-243.
4. Saruhan-Direskeneli G, Kilic A, Parman Y, Serdaroglu P, Deymeer F. HLA-DQ polymorphism in Turkish patients with myasthenia gravis. Hum Immunol 2006;67:352-358.
5. Somnier FE, Keiding N, Paulson OB. Epidemiology of myasthenia gravis in Denmark. A longitudinal and comprehensive population survey. Arch Neurol 1991;48:733-739.
6. Evoli A, Batocchi AP, Minisci C, Di Schino C, Tonali P. Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 2000;48:1442-1448.
7. Ishii W, Matsuda M, Hanyuda M, Momose M, Nakayama J, Ehara T, et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci 2007;14:110-115.
8. Pakzad Z, Aziz T, Oger J. Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 2011;76:1526-1528.
9. Viets HR. A historical review of myasthenia gravis from 1672 to 1900. JAMA 1953;153:1273-1280.
10. Campbell H, Bramwell E. Myasthenia gravis. Critical Digest 1900;23:277-336.
11. Havard CW. Diseases of the central nervous system. Myasthenia gravis. BMJ 1975;4:152-154.
12. Hokkanen E. Epidemiology of myasthenia gravis in Finland. J Neurol Sci 1969;9:463-478.
13. Schwab RS, Leland CC. Sex and age in myasthenia gravis as critical factors in incidence and remission. JAMA 1953;153:1270-1273.
14. Benatar M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul Disord 2006;16:459-467.
15. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365-368.
16. Guptill JG, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011;44:36-40.
17. Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012;69:445-451.
18. Cavalcante P, Le Panse R, Berrih-Aknin S, Maggi L, Antozzi C, Baggi F, et al. The thymus in myasthenia gravis: site of "innate autoimmunity"? Muscle Nerve 2011;44:467-484.
19. Drachman DB. Myasthenia gravis. N Engl J Med 1994;330:1797-1810.
20. Murai H, Yamashita N, Watanabe M, Nomura Y, Motomura M, Yoshikawa H, et al. Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey. J Neurol Sci 2011;305:97-102.
21. Tsuchida M, Yamato Y, Souma T, Yoshiya K, Watanabe T, Aoki T, et al. Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 1999;67:1563-1567.
22. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol 2004;5:133-139.
23. Limburg PC, The TH, Hummel-Tappel E, Oosterhuis HJ. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 1. Relation to clinical parameters in 250 patients. J Neurol Sci 1983;58:357-370.
24. Mantegazza R, Pareyson D, Baggi F, Romagnoli P, Peluchetti D, Sghirlanzoni A, et al. Anti AChR antibody: relevance to diagnosis and clinical aspects of myasthenia gravis. Ital J Neurol Sci 1988;9:141-145.
25. Kapinas K, Kimiskidis VK, Kazis AD, Kokkas B, Tsolaki M, Georgiadis G. Myasthenia gravis: correlation of age with clinical course and anti-AChR antibody levels. Int J Immunopathol Pharmacol 1999;12:127-131.
26. Suzuki S, Utsugisawa K, Nagane Y, Satoh T, Kuwana M, Suzuki N. Clinical and immunological differences between early and late-onset myasthenia gravis in Japan. J Neuroimmunol 2011;230:148-152.
27. Zivkovic SA, Clemens PR, Lacomis D. Characteristics of late-onset myasthenia gravis. J Neurol 2012;259:2167-2171.
28. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011;2011:740583.
29. Romi F, Skeie GO, Aarli JA, Gilhus NE. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000;247:369-375.
30. Romi F, Skeie GO, Aarli JA, Gilhus NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000;57:1596-1600.
31. Vincent A, Clover L, Buckley C, Grimley Evans J, Rothwell PM. Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 2003;74:1105-1108.
32. Donaldson DH, Ansher M, Horan S, Rutherford RB, Ringel SP. The relationship of age to outcome in myasthenia gravis. Neurology 1990;40:786-790.
33. Sommer N, Melms A, Weller M, Dichgans J. Ocular myasthenia gravis. A critical review of clinical and pathophysiological aspects. Doc Ophthalmol 1993;84:309-333.
34. Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 2008;37:300-307.
35. Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984;15:291-298.
36. Antonini G, Morino S, Gragnani F, Fiorelli M. Myasthenia gravis in the elderly: a hospital based study. Acta Neurol Scand 1996;93:260-262.
37. Slesak G, Melms A, Gerneth F, Sommer N, Weissert R, Dichgans J. Late-onset myasthenia gravis. Follow-up of 113 patients diagnosed after age 60. Ann NY Acad Sci 1998;841:777-780.
38. Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998;50:1778-1783.
39. Kuks JB, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul Disord 1991;1:423-431.
40. Ponseti JM, Gamez J, Azem J, Lopez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann NY Acad Sci 2008;1132:254-263.
41. Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med 1987;316:719-724.
42. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010;17:893-902.
43. Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008;71:394-399.
44. Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008;71:400-406.
45. Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2012;12:CD002277.
46. Abdel-Rahman EM, Hayes J, Balogun RA. Therapeutic plasma exchange in the elderly: experience at a tertiary center. J Clin Apher 2012;27:108-111.
47. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004;83:661-665.
48. Kattach H, Anastasiadis K, Cleuziou J, Buckley C, Shine B, Pillai R, et al. Transsternal thymectomy for myasthenia gravis: surgical outcome. Ann Thorac Surg 2006;81:305-308.
49. Calhoun RF, Ritter JH, Guthrie TJ, Pestronk A, Meyers BF, Patterson GA, et al. Results of transcervical thymectomy for myasthenia gravis in 100 consecutive patients. Ann Surg 1999;230:555-559.
50. Masaoka A, Monden Y. Comparison of the results of transsternal simple, transcervical simple, and extended thymectomy. Ann NY Acad Sci 1981;377:755-765.
51. Marulli G, Rea F, Melfi F, Schmid TA, Ismail M, Fanucchi O, et al. Robot-aided thoracoscopic thymectomy for early-stage thymoma: a multicenter European study. J Thorac Cardiovasc Surg 2012;144:1125-1130.
52. Jurado J, Javidfar J, Newmark A, Lavelle M, Bacchetta M, Gorenstein L, et al. Minimally invasive thymectomy and open thymectomy: outcome analysis of 263 patients. Ann Thorac Surg 2012;94:974-981.
53. Castro D, Derisavifard S, Anderson M, Greene M, Iannaccone S. Juvenile myasthenia gravis: a twenty-year experience. J Clin Neuromuscul Dis 2013;14:95-102.
54. Perlo VP, Arnason B, Castleman B. The thymus gland in elderly patients with myasthenia gravis. Neurology 1975;25:294-295.
55. Katzberg HD, Aziz T, Oger J. In myasthenia gravis cells from atrophic thymus secrete acetylcholine receptor antibodies. Neurology 2001;56:572-573.
56. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009;41:67-76.
57. Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve 2008;37:141-149.
58. Mantegazza R, Beghi E, Pareyson D, Antozzi C, Peluchetti D, Sghirlanzoni A, et al. A multicentre follow-up study of 1152 patients with myasthenia gravis in Italy. J Neurol 1990;237:339-344.
59. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 2003;998:413-423.
60. Beghi E, Antozzi C, Batocchi AP, Cornelio F, Cosi V, Evoli A, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci 1991;106:213-220.
61. Durelli L, Maggi G, Casadio C, Ferri R, Rendine S, Bergamini L. Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients. J Neurol Neurosurg Psychiatry 1991;54:406-411.
62. Cosi V, Romani A, Lombardi M, Raiola E, Bergamaschi R, Piccolo G, et al. Prognosis of myasthenia gravis: a retrospective study of 380 patients. J Neurol 1997;244:548-555.
63. Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 2010;17:913-921.
64. Chan KH, Cheung RT, Mak W, Ho SL. Nonthymoma early-onset- and late-onset-generalized myasthenia gravis-a retrospective hospital-based study. Clin Neurol Neurosurg 2007;109:686-691.